LCTX - Lineage Cell Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

174.9M

Cash

46.81M

Avg Qtr Burn

-8.022M

Short % of Float

3.51%

Insider Ownership

4.44%

Institutional Own.

38.36%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OpRegen® (RPE Cells) Details Dry eye disease , Age-related macular degeneration	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OPC1 (Oligodendrocytes) Details Spine disorder, Spinal cord injury	Phase 1 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VAC2 (Dendritic Cells) Details Non-small cell lung carcinoma, Lung cancer, Lung disease	Phase 1 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.